Literature DB >> 29524006

Remote ischemic preconditioning fails to reduce infarct size in the Zucker fatty rat model of type-2 diabetes: role of defective humoral communication.

Joseph Wider1,2,3,4, Vishnu V R Undyala1, Peter Whittaker1,3, James Woods2, Xuequn Chen2, Karin Przyklenk5,6,7.   

Abstract

Remote ischemic preconditioning (RIPC), the phenomenon whereby brief ischemic episodes in distant tissues or organs render the heart resistant to infarction, has been exhaustively demonstrated in preclinical models. Moreover, emerging evidence suggests that exosomes play a requisite role in conveying the cardioprotective signal from remote tissue to the myocardium. However, in cohorts displaying clinically common comorbidities-in particular, type-2 diabetes-the infarct-sparing effect of RIPC may be confounded for as-yet unknown reasons. To investigate this issue, we used an integrated in vivo and in vitro approach to establish whether: (1) the efficacy of RIPC is maintained in the Zucker fatty rat model of type-2 diabetes, (2) the humoral transfer of cardioprotective triggers initiated by RIPC are transported via exosomes, and (3) diabetes is associated with alterations in exosome-mediated communication. We report that a standard RIPC stimulus (four 5-min episodes of hindlimb ischemia) reduced infarct size in normoglycemic Zucker lean rats, but failed to confer protection in diabetic Zucker fatty animals. Moreover, we provide novel evidence, via transfer of serum and serum fractions obtained following RIPC and applied to HL-1 cardiomyocytes subjected to hypoxia-reoxygenation, that diabetes was accompanied by impaired humoral communication of cardioprotective signals. Specifically, our data revealed that serum and exosome-rich serum fractions collected from normoglycemic rats attenuated hypoxia-reoxygenation-induced HL-1 cell death, while, in contrast, exosome-rich samples from Zucker fatty rats did not evoke protection in the HL-1 cell model. Finally, and unexpectedly, we found that exosome-depleted serum from Zucker fatty rats was cytotoxic and exacerbated hypoxia-reoxygenation-induced cardiomyocyte death.

Entities:  

Keywords:  Cardioprotection; Exosomes; Extracellular vesicles; Infarct size; Mass spectrometry; Myocardial infarction; Myocardial ischemia; Proteomics; Remote ischemic preconditioning; Type-2 diabetes

Mesh:

Year:  2018        PMID: 29524006      PMCID: PMC6776086          DOI: 10.1007/s00395-018-0674-1

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  89 in total

1.  Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection.

Authors:  Sanyukta Rana; Shijing Yue; Daniela Stadel; Margot Zöller
Journal:  Int J Biochem Cell Biol       Date:  2012-06-19       Impact factor: 5.085

2.  Preconditioning-induced cardioprotection and release of the second messenger inositol (1,4,5)-trisphosphate are both abolished by neomycin in rabbit heart.

Authors:  B Bauer; B Z Simkhovich; R A Kloner; K Przyklenk
Journal:  Basic Res Cardiol       Date:  1999-02       Impact factor: 17.165

3.  Cardioprotection by Remote Ischemic Preconditioning is Blocked in the Aged Rat Heart in Vivo.

Authors:  Friederike Behmenburg; André Heinen; Lilli Vom Bruch; Markus W Hollmann; Ragnar Huhn
Journal:  J Cardiothorac Vasc Anesth       Date:  2016-07-07       Impact factor: 2.628

4.  Intramyocardial injections and protection against myocardial ischemia. An attempt to examine the cardioprotective actions of adenosine.

Authors:  P Whittaker; R A Kloner; K Przyklenk
Journal:  Circulation       Date:  1996-06-01       Impact factor: 29.690

5.  Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation.

Authors:  E Kottenberg; M Thielmann; P Kleinbongard; U H Frey; T Heine; H Jakob; G Heusch; J Peters
Journal:  Acta Anaesthesiol Scand       Date:  2014-02-18       Impact factor: 2.105

6.  ApolipoproteinE mimetic peptides improve outcome after focal ischemia.

Authors:  Haichen Wang; Lauren G Anderson; Christopher D Lascola; Michael L James; Talaignair N Venkatraman; Ellen R Bennett; Shawn K Acheson; Michael P Vitek; Daniel T Laskowitz
Journal:  Exp Neurol       Date:  2012-12-06       Impact factor: 5.330

7.  Improvement of neuronal cell survival by astrocyte-derived exosomes under hypoxic and ischemic conditions depends on prion protein.

Authors:  Kathrin Guitart; Gabriele Loers; Friedrich Buck; Ute Bork; Melitta Schachner; Ralf Kleene
Journal:  Glia       Date:  2016-03-16       Impact factor: 7.452

8.  Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome.

Authors:  Abdelali Agouni; Anne Hélène Lagrue-Lak-Hal; Pierre Henri Ducluzeau; Hadj Ahmed Mostefai; Catherine Draunet-Busson; Georges Leftheriotis; Christophe Heymes; Maria Carmen Martinez; Ramaroson Andriantsitohaina
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

Review 9.  Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning.

Authors:  Takayuki Miki; Takahito Itoh; Daisuke Sunaga; Tetsuji Miura
Journal:  Cardiovasc Diabetol       Date:  2012-06-13       Impact factor: 9.951

10.  Remote ischemic preconditioning (RIPC) modifies plasma proteome in humans.

Authors:  Michele Hepponstall; Vera Ignjatovic; Steve Binos; Paul Monagle; Bryn Jones; Michael H H Cheung; Yves d'Udekem; Igor E Konstantinov
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

View more
  27 in total

Review 1.  Extracellular vesicles in cardiovascular diseases.

Authors:  Shihui Fu; Yujie Zhang; Yulong Li; Leiming Luo; Yali Zhao; Yao Yao
Journal:  Cell Death Discov       Date:  2020-07-30

Review 2.  Biomimetic and immunomodulatory therapeutics as an alternative to natural exosomes for vascular and cardiac applications.

Authors:  Ramiro A Villarreal-Leal; John P Cooke; Bruna Corradetti
Journal:  Nanomedicine       Date:  2021-03-24       Impact factor: 6.096

3.  The YAP/SERCA2a signaling pathway protects cardiomyocytes against reperfusion-induced apoptosis.

Authors:  Jiankai Zhong; Haichun Ouyang; Sulin Zheng; Zhongzhou Guo; Yuying Chen; Yuanlin Zhong; Wenhao Zhong; Liuer Zuo; Jianhua Lu
Journal:  Aging (Albany NY)       Date:  2020-07-09       Impact factor: 5.682

Review 4.  Extracellular vesicles in cardiovascular diseases.

Authors:  Shihui Fu; Yujie Zhang; Yulong Li; Leiming Luo; Yali Zhao; Yao Yao
Journal:  Cell Death Discov       Date:  2020-07-30

Review 5.  Examining the Paracrine Effects of Exosomes in Cardiovascular Disease and Repair.

Authors:  Melanie Gartz; Jennifer L Strande
Journal:  J Am Heart Assoc       Date:  2018-06-01       Impact factor: 5.501

Review 6.  New advances in perioperative cardioprotection.

Authors:  Mona Momeni; Stefan De Hert
Journal:  F1000Res       Date:  2019-04-24

7.  DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome.

Authors:  Yochai Birnbaum; Dat Tran; Mandeep Bajaj; Yumei Ye
Journal:  Basic Res Cardiol       Date:  2019-08-06       Impact factor: 17.165

8.  Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models.

Authors:  Zhenhong Fu; David Mui; Hang Zhu; Ying Zhang
Journal:  Aging (Albany NY)       Date:  2020-05-11       Impact factor: 5.682

9.  Remote Ischemic Pre-Conditioning Attenuates Adverse Cardiac Remodeling and Mortality Following Doxorubicin Administration in Mice.

Authors:  Zachary M Gertz; Chad Cain; Donatas Kraskauskas; Teja Devarakonda; Adolfo G Mauro; Jeremy Thompson; Arun Samidurai; Qun Chen; Sarah W Gordon; Edward J Lesnefsky; Anindita Das; Fadi N Salloum
Journal:  JACC CardioOncol       Date:  2019-12-17

10.  Evaluation of the cardioprotective potential of extracellular vesicles - a systematic review and meta-analysis.

Authors:  Sebastian Wendt; Andreas Goetzenich; Claudia Goettsch; Christian Stoppe; Christian Bleilevens; Sandra Kraemer; Carina Benstoem
Journal:  Sci Rep       Date:  2018-10-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.